Nivolumab for Pediatric and Adult Relapsing/Refractory ALK+, for Evaluation of Response in Patients With Progressive Disease (Cohort 1) or as Consolidative Immunotherapy in Patients in Complete Remission After Relapse (Cohort 2)

NCT03703050 · clinicaltrials.gov ↗

PHASE2

Phase

ACTIVE_NOT_RECRUITING

Status

45

Enrollment

OTHER

Sponsor class

Conditions

Relapsing/Refractory ALK+ Anaplastic Large Cell Lymphoma

Interventions

DRUG: Nivolumab cohort 1
DRUG: Nivolumab cohort 2

Sponsor

Gustave Roussy, Cancer Campus, Grand Paris